Oneview collaborative partner NYU Langone praises CXP technology

|

Published 10-MAY-2021 15:14 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Oneview Healthcare’s (ASX: ONE) technology partner NYU Langone Health has released an informative webinar, discussing the group’s digital patient experience strategy and how Oneview Healthcare’s Care Experience Platform has helped improve patient, family and clinician experience.

Leveraging the latest digital tools and patient-facing technologies, NYU Langone has transformed the care experience for caregivers, patients and their families where it matters most – at the bedside.

With large electronic display screens and bedside tablets at every bedside, patients can connect virtually while accessing virtual language and interpretation services.

Through these services, patients are also able to perform tasks such as the ordering and scheduling of meals, the control of lights and temperature and gain access to personalised education, entertainment and distraction programming from a single user interface.

The significance of an endorsement from NYU Langone can’t be understated as the group partnered with Oneview Healthcare in developing its cloud-based platform CXP Cloud Enterprise, a key pillar of the group’s growth strategy and a technology that will assist in transforming the hospital experience for patients, families and care teams.

Together, NYU Langone and Oneview collaborated on the initial cloud-based version that enabled NYU Langone to implement key capabilities across 400 beds in just weeks.

NYU Langone is a strong supporter of Oneview and the broader virtual care experience with executive Vice President Nader Mherab recently saying, “NYU Langone Health is committed to delivering the best possible care experience for our patients, including through virtual care,”

"COVID-19 strained resources and challenged most hospitals to examine how virtual pathways can enhance patient care.

"Oneview helped us build an in-patient virtual care platform, which has been instrumental during the pandemic and will continue to be key as we deliver a new level of patient engagement.”

Benefits of CXP extend beyond the COVID crisis

It was just over a month ago that Oneview Healthcare launched CXP Cloud Enterprise, the world’s first and only cloud-based care experience platform.

Deployed on Microsoft Azure, this platform enables health systems to quickly adopt technology for engaging patients, reducing non-clinical demands on care teams and optimising clinical and operational effectiveness.

The launch of the new technology was very timely, meeting the demands for digital services driven by the COVID pandemic.

Particularly in the longer term, the benefits of the CXP Cloud Enterprise platform being developed in partnership with NYU Langone Health will become increasingly visible, especially given the group’s position as a leading academic medical centre in New York.

NYU Langone Health rapidly rolled out the virtual engagement platform across its facilities during the COVID-19 pandemic to address the increased pressure on care teams and patient’s restricted access to family and friends.

Similarly, CXP Cloud Enterprise enables health systems to quickly adopt technology for engaging patients, reducing non-clinical demands on care teams and optimising clinical and operational effectiveness.

This comes at a critical time to meet the demand for digital services driven by the pandemic.

The cloud-based platform provides competitive benefits, being the first and only cloud-based care experience solution providing Oneview with a strong commercial advantage, as well as allowing health systems that have adopted the technology at an early stage to rapidly implement the capabilities that meet their needs today.

The technology also allows health providers to adapt to a dynamic environment, providing the agility, scalability and investment protection to grow as their health system changes.

Dr Simon Kos, Healthcare Industry Executive, Microsoft Australia summed up the significance of the development in saying, “The cloud enablement of Oneview's patient experience platform is a game changer.

“It means that health organisations can deploy more quickly, with greater predictability and less specialised resources, all on the trusted Azure cloud.

‘’This is a win for patients, clinicians and healthcare organisations that put patient experience and outcomes first.”

As highlighted in NYU’s webinar, Oneview tablets played a significant role at a time when the resources of hospitals were stretched.

Post-pandemic, NYU is working on a strategy to develop standard software packages with testing automation that provides a continuous integration and delivery pipeline.

This will require a variety of device types, as well as differentiated mountings.

The company indicated in the course of its webinar that flexibility allowed for rapid iteration and adaptation to changing needs, and importantly for Oneview, cloud and automation reduces deployment time.

The following illustrates NYU’s diversified range of medical service facilities, effectively highlighting the strong focus that is likely to be shared with its collaborative partners such as Oneview in developing flexible solutions.

For more information: Top 10 US Hospital Endorses ONE’s Health Tech



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X